Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

By sjmartinez • September 27, 2022

Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 Aug 19:S1558-7673(22)00174-4. doi: 10.1016/j.clgc.2022.08.006. Epub ahead of print. PMID: 36155169.

Tags: Bladder cancer, Checkpoint Inhibitor, Hematology/Oncology, immunotherapy, Outcomes, Platinum resistance, Publications

CD146+ pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis

Liu W, Duan W, Xia S, Liu Y, Chu H, Liang K, Fang S, Lin M, Wei S, You X, Hu Q, Qi J, Wang[...]

Phosphatidylserine receptors TIM-1 and AXL mediate tick-borne Powassan virus entry

Daskou M, Zaiss AK, Jeyachandran AV, Takano KA, Kan RL, Paravastu R, Gerald E, Satheeshkumar N, Rios-Rodriguez J, Russell B, Brault AC, Bhaduri A, Garcia[...]

Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration

Rosen LS, Ottensmeier C, Hawkins M, Naing A, Sonpavde G, Van Tine BA, Parkes EE, O'Cathail SM, Ji RR, Thomas M, Stacey A, Sasso MS,[...]